Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Antolitinic/Sintilimab Combination Under Investigation for OCCC in China

March 18th 2022

Chinese investigators have launched CC-ANNIE, a phase 2 trial exploring anlotinib plus sintilimab for women with recurrent platinum-resistant ovarian clear cell carcinoma.

Real-World Analysis Shows Survival Benefit With Second-Line PARP Maintenance Over Active Surveillance in Ovarian Cancer

March 18th 2022

Patients with recurrent ovarian cancer who received PARP inhibitor maintenance treatment in the second-line setting experienced a longer time to next treatment and overall survival compared with those who were just under active surveillance.

Dr. Olawaiye on Front Line Treatment Sequencing Considerations in Ovarian Cancer

March 15th 2022

Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.

Gynecologic Malignancies Management Makes Significant Strides With ADCs, PARP Inhibitors, and Checkpoint Blockade

March 14th 2022

Alexander Babatunde Olawaiye, MD, discusses frontline and second-line maintenance in ovarian cancer, the role of surgery in platinum-sensitive disease, and updates in cervical and endometrial cancers.

Dr. Birrer on Remaining Questions in Platinum-Sensitive Ovarian Cancer

March 12th 2022

Michael J. Birrer, MD, PhD, discussed remaining questions when addressing platinum-sensitive ovarian cancer.

Trametinib Represents a New Standard-of-Care Option in Recurrent Low-Grade Serous Ovarian Carcinoma

March 1st 2022

The MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared with current standard-of-care therapies in patients with relapsed or persistent low-grade serous ovarian carcinoma, making it the potential new SOC for this patient population.

Jain Talks Patient Management, Dosing, and Toxicity Mitigation With Frontline PARP Maintenance in Ovarian Cancer

February 24th 2022

Dr Jain discusses the current utility of frontline maintenance therapy in advanced ovarian cancer, dosing strategies with PARP inhibitors, and management strategies for common adverse effects associated with these therapies.

Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer

February 23rd 2022

The combination of ixabepilone and bevacizumab significantly improved progression-free survival vs ixabepilone alone in the treatment of platinum-resistant ovarian cancer, according to data from the phase 2 trial published in the British Journal of Cancer.

Dr. Moore on BCMA-Mutation Testing in Ovarian Cancer

February 23rd 2022

Kathleen Moore, MD, discusses current standard of care in treating ovarian cancer.

Safety Review for OVATION 2 Trial Examining GEN-1 in Advanced Ovarian Cancer Has Positive Results

February 22nd 2022

The Data Safety Monitoring Board for the ongoing phase 1/2 OVATION 2 trial has unanimously recommended that patients continue to receive treatment with the novel gene-mediated immunotherapy, GEN-1, at a dose of 100 mg/m2.

Dr. Brown on the Benefits of Minimally Invasive Surgery in Ovarian Cancer

February 17th 2022

Jubilee Brown, MD, discusses the benefits of minimally invasive surgery in ovarian cancer.

The Future of Ovarian Cancer Treatment

February 17th 2022

Oncologists contemplate what ovarian cancer treatment will look like in the future and exciting clinical trials in progress.

Ovarian Cancer Maintenance Therapy Clinical Pearls

February 10th 2022

Robert W. Holloway, MD, and Chad A. Hamilton, MD, provide clinical pearls for community physicians using maintenance therapies for ovarian cancer.

Ovarian Cancer Maintenance Therapy: Olaparib vs. Niraparib

February 10th 2022

Key opinion leaders discuss how they decide between two regimens for ovarian cancer maintenance therapies.

Case Scenario: Stage 3C High-Grade Serous Ovarian Cancer

February 3rd 2022

Experts review the potential maintenance therapy approaches for a 64-year-old woman with stage IIIC high-grade serous ovarian cancer.

Ovarian Cancer: Significant Clinical Trials

February 3rd 2022

Dr. Chad Hamilton explains pivotal data from several important clinical trials in ovarian cancer.

Dr. Richardson on the Rationale for the UPNEXT Trial in Ovarian Cancer

February 2nd 2022

Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.

Frontline Maintenance Requires Careful Consideration in Advanced Ovarian Cancer

February 1st 2022

Alexander Babatunde Olawaiye, MD, discusses factors that influence optimized frontline maintenance therapy in advanced ovarian cancer.

Virtual Surveillance Visits with Symptom, Serum CA-125 Review May Offer Alternative for Ovarian Cancer Recurrence Detection.

February 1st 2022

In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.

Secondary Cytoreductive Surgery Requires Careful Selection in Recurrent Ovarian Cancer

January 31st 2022

Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.